Advertisement
Advertisement
U.S. markets open in 7 hours 19 minutes
S&P Futures
3,860.25 +12.00 (+0.31%) Dow Futures
31,109.00 +96.00 (+0.31%) Nasdaq Futures
11,928.50 +48.25 (+0.41%) Russell 2000 Futures
1,735.60 +7.00 (+0.40%) Crude Oil
98.82 +0.29 (+0.29%) Gold
1,744.20 +7.70 (+0.44%)
Reata Pharmaceuticals, Inc. (RETA)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 36.49 |
| Open | 36.39 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 1800 |
| Day's Range | 35.35 - 37.97 |
| 52 Week Range | 20.24 - 143.08 |
| Volume | |
| Avg. Volume | 481,066 |
| Market Cap | 1.331B |
| Beta (5Y Monthly) | 1.24 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.35 |
| Earnings Date | Aug 08, 2022 - Aug 12, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 57.11 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Subscribe to Yahoo Finance Plus to view Fair Value for RETA
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Reata Pharmaceuticals, Inc.Daily – Vickers Top Buyers & Sellers for 01/05/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat6 months agoArgus Research
- Simply Wall St.
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) may have lost US$207m in value but insiders who invested last year have seen gains of around US$44k to date
Insiders who bought Reata Pharmaceuticals, Inc. ( NASDAQ:RETA ) stock lover the last 12 months are probably not as...
- Zacks
Why Is Reata Pharmaceuticals, Inc. (RETA) Up 53.1% Since Last Earnings Report?
Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Reata (RETA) Up More Than 12% YTD: What's Driving the Rally?
Reata's (RETA) prospects are likely to improve following the potential approval of its lead candidate, omaveloxolone, expected by the end of 2022 is likely driving its share price.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
